Protalix BioTherapeutics (PLX) Work In Process (2012 - 2026)

Protalix BioTherapeutics' Work In Process history runs 9 years deep, the most recent figure standing at $9.1 million for Q1 2026.

• On a quarterly basis, Work In Process rose 13.51% year-over-year to $9.1 million in Q1 2026; TTM through Mar 2026 was $9.1 million, a 13.51% increase from a year earlier, with the FY2025 full-year figure at $9.4 million, down 16.63% from the prior year.
• Work In Process declined to $9.1 million in Q1 2026 per PLX's latest filing, from $9.4 million in the prior quarter.
• Across five years, Work In Process topped out at $12.3 million in Q3 2024 and bottomed at $1.5 million in Q1 2023.
• The 5-year median for Work In Process is $8.1 million (2025), against an average of $7.0 million.
• Across the five-year window, Work In Process soared 498.11% in 2024 and sank 56.29% in 2025, its largest moves.
• Year by year, Work In Process stood at $2.7 million in 2022, then surged by 238.13% to $9.1 million in 2023, then grew by 24.19% to $11.2 million in 2024, then declined by 16.63% to $9.4 million in 2025, then declined by 3.11% to $9.1 million in 2026.
• Per Business Quant, the three latest PLX Work In Process figures stand at $9.1 million (Q1 2026), $9.4 million (Q4 2025), and $5.4 million (Q3 2025).